PSMA4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL605949	0.54	15/20
SCHEMBL607010	0.56	12/20
SCHEMBL609327	0.55	12/20
SCHEMBL607553	0.54	12/20
SCHEMBL606932	0.53	12/20
SCHEMBL608381	0.53	12/20
SCHEMBL609081	0.52	12/20
SCHEMBL606926	0.52	12/20
SCHEMBL606344	0.51	12/20
SCHEMBL606616	0.51	12/20
SCHEMBL1327404	0.50	12/20
SCHEMBL607035	0.61	11/20
SCHEMBL609733	0.60	11/20
SCHEMBL609324	0.60	11/20
SCHEMBL605158	0.59	11/20
SCHEMBL606315	0.59	11/20
SCHEMBL609290	0.57	11/20
SCHEMBL607972	0.55	11/20
SCHEMBL608782	0.54	11/20
SCHEMBL609278	0.54	11/20

Clinical trials — most relevant to PSMA4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer	PHASE2	COMPLETED
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	PHASE2	COMPLETED
Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT	PHASE1/PHASE2	COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer	PHASE2	COMPLETED
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:	PHASE2	ACTIVE_NOT_RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
Quantification of GADD34 Expression in RA	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007	nan	COMPLETED
Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15	nan	UNKNOWN
PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas	nan	COMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMA4 binder may also engage these)

Protein	Name	Similarity
Q9R1P0	—	1.000	Q9R1P0 →
Q4R932	—	1.000	Q4R932 →
Q3ZCK9	—	1.000	Q3ZCK9 →
P21670	—	1.000	P21670 →
Q8SRU7	—	1.000	Q8SRU7 →
P18053	—	1.000	P18053 →
Q9N599	—	0.999	Q9N599 →
Q27488	—	0.998	Q27488 →
O16811	—	0.998	O16811 →
P34119	—	0.997	P34119 →
O73672	—	0.996	O73672 →
Q9GU37	—	0.995	Q9GU37 →
P32379	—	0.995	P32379 →
PSMA2	Proteasome subunit alpha type-2	0.995	landscape →
P23638	—	0.995	P23638 →
Q3T0X5	—	0.994	Q3T0X5 →
Q5REN2	—	0.994	Q5REN2 →
O13268	—	0.994	O13268 →
Q24178	—	0.994	Q24178 →
Q54XM7	—	0.993	Q54XM7 →
O82530	—	0.993	O82530 →
P40301	—	0.993	P40301 →
O81148	—	0.993	O81148 →
Q27563	—	0.993	Q27563 →
P90513	—	0.993	P90513 →
O14250	—	0.993	O14250 →
PSMA1	Proteasome subunit alpha type-1	0.993	landscape →
Q4R3H2	—	0.993	Q4R3H2 →
Q10KF0	—	0.993	Q10KF0 →
Q8L4A7	—	0.992	Q8L4A7 →